Aldeyra Therapeutics (ALDX) Stock Price, News & Analysis

Company Overview

Aldeyra Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis. Aldeyra is also developing ADX-2191, an intravitreal formulation targeting proliferative vitreoretinopathy, a serious complication of retinal detachment surgery. In addition to its ophthalmology pipeline, Aldeyra has earlier-stage programs exploring systemic indications where reactive aldehyde species contribute to inflammation and tissue damage.

Founded in 2009 and headquartered in Lexington, Massachusetts, Aldeyra is led by a management team with extensive experience in ophthalmology and biopharmaceutical development. Under the leadership of Chief Executive Officer Fredric A. Hargreaves, the company collaborates with clinical research centers across North America and Europe to advance its pipeline through late-stage clinical trials. Aldeyra’s strategy emphasizes rigorous clinical validation, strategic partnerships and readiness for commercial launch upon regulatory approval.

Key Stats

• Today's Range: $1.52 to $1.63
• 50-Day Range: $1.52 to $2.43
• 52-Week Range: $1.07 to $6.18
• Volume: 576,770 shs
• Average Volume: 1.33 million shs
• Market Capitalization: $92.89 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.50
• Consensus Rating: Hold

Aldeyra Therapeutics Stock Analysis - MarketRank™

Aldeyra Therapeutics scored higher than 71% of companies evaluated by MarketBeat, and ranked 213th out of 894 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Aldeyra Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.

Upside Potential

Aldeyra Therapeutics has a consensus price target of $5.50, representing about 257.1% upside from its current price of $1.54.

Amount of Analyst Coverage

Aldeyra Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aldeyra Therapeutics are expected to grow in the coming year, from ($0.43) to ($0.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aldeyra Therapeutics is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aldeyra Therapeutics is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aldeyra Therapeutics has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.76% of the float of Aldeyra Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aldeyra Therapeutics has a short interest ratio ("days to cover") of 1.99, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aldeyra Therapeutics has recently decreased by 36.66%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aldeyra Therapeutics does not currently pay a dividend.

Dividend Growth

Aldeyra Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.96

News Sentiment

Aldeyra Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Aldeyra Therapeutics this week, compared to 6 articles on an average week.

Search Interest

Only 3 people have searched for ALDX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Aldeyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 4.0 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $417,500.00 in company stock, which represents 0.4494% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Aldeyra Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $417,500.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

11.80% of the stock of Aldeyra Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

59.71% of the stock of Aldeyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 8/03/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ALDX
• CIK: 1341235
• Web: www.ampliphibio.com
• Phone: 781-761-4904
• Fax: 781-270-0630
• Employees: 10
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Aldeyra Therapeutics: $5.50
• High Price Target: $9.00
• Low Price Target: $2.00
• Potential Upside/Downside: +257.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$33.85 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -57.34%
• Return on Assets: -36.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.72
• Quick Ratio: 2.72

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.74 per share
• Price / Book: 2.08

Miscellaneous

• Outstanding Shares: 60,320,000
• Free Float: 53,203,000
• Market Cap: $92.89 million
• Optionable: Optionable
• Beta: 1.22